Government-Owned Inventions; Availability for Licensing, 38707 [2018-16839]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices
Program (CICP) to provide benefits to
certain individuals or estates of
individuals who sustain a covered
serious physical injury as the direct
result of the administration or use of the
Covered Countermeasures, and benefits
to certain survivors of individuals who
die as a direct result of the
administration or use of the Covered
Countermeasures. The causal
connection between the countermeasure
and the serious physical injury must be
supported by compelling, reliable, valid,
medical and scientific evidence in order
for the individual to be considered for
compensation. The CICP is
administered by the Health Resources
and Services Administration, within the
Department of Health and Human
Services. Information about the CICP is
available at the toll-free number 1–855–
266–2427 or https://www.hrsa.gov/cicp/.
XV. Amendments
Amendments to this Declaration will
be published in the Federal Register.
Dated: August 1, 2018.
Alex M. Azar II
Secretary, Department of Health and Human
Services.
[FR Doc. 2018–16856 Filed 8–6–18; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
daltland on DSKBBV9HB2PROD with NOTICES
[FR Doc. 2018–16787 Filed 8–6–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Initial Review Group; Clinical Aging
Review Committee NIA–C.
Date: September 27–28, 2018.
Time: 3:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Jkt 244001
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Authority: 42 U.S.C. 247d–6d.
16:54 Aug 06, 2018
Dated: August 1, 2018.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
Government-Owned Inventions;
Availability for Licensing
42 U.S.C. 247d–6d(b)(4)
VerDate Sep<11>2014
Place: Bethesda Marriott, 5151 Pooks Hill
Rd., Bethesda, MD 20814.
Contact Person: Alicja L. Markowska,
Ph.D., DSC, National Institute on Aging,
National Institutes of Health, Gateway
Building 2C212, 7201 Wisconsin Avenue,
Bethesda, MD 20892, 301–496–9666,
markowsa@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by emailing the indicated licensing
contact at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION: This
notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
commercialization of results of
federally-funded research and
development.
Technology description follows.
SUMMARY:
Neuroendocrine Tumor Evans Blue
Containing Radiotherapeutics
The invention pertains to a
radiotherapeutic against neuroendocrine
tumors that express somatostatin
receptor. Radionuclide therapies
directed against tumors that express
somatostatin receptors (SSTRs) have
proven effective for the treatment of
advanced, low- to intermediate-grade
neuroendocrine tumors. The subject
radiotherapeutic covered by the subject
patent estate includes a somatostatin
(SST) peptide derivative like octreotate
(TATE), conjugated to an Evans Blue
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
38707
(EB) analog, and further chelated via
DOTA to therapeutic radionuclide177Lu,
a beta emitter. The EB analog reversibly
binds to circulating serum albumin and
improves the pharmacokinetics of SST
peptide derivatives and reduce peptidereceptor radionuclide therapy toxicity.
EB analog conjugated to octreotate (EB–
DOTATATE) has been shown by the
inventors to provide reversible albumin
binding in vivo and extended half-life in
circulation. When EB–TATE is slowly
released into the tumor
microenvironment, tumor uptake and
internalization into SSTR positive
tumors resulted in delivery of
radioactive particles and tumor cell
killing. EB–TATE displayed
significantly more favorable
pharmacokinetics than TATE alone by
achieving higher tumor to non-tumor
penetration as evidenced by positron
emission tomography.
Potential Commercial Applications:
• Cancer therapeutics
• Higher stability/Lower toxicity
Development Stage:
• Early stage
Inventors: Xiaoyuan Chen and Orit
Jacobson Weiss (both of NIBIB).
Intellectual Property: HHS Reference
No. E–150–2016–1; International Patent
Application PCT/US2017/031696.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Dated: July 20, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2018–16839 Filed 8–6–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Treatment of Type I Diabetes
and its Comorbidities
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent License to Inversago Pharma,
Inc., located in Montreal, Quebec,
Canada, to practice the inventions
embodied in the patent applications
SUMMARY:
E:\FR\FM\07AUN1.SGM
07AUN1
]]>Agencies
[Federal Register Volume 83, Number 152 (Tuesday, August 7, 2018)]
[Notices]
[Page 38707]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16839]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development Office
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda,
MD 20892-2479; telephone: 301-402-5579. A signed Confidential
Disclosure Agreement may be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve commercialization of results of
federally-funded research and development.
Technology description follows.
Neuroendocrine Tumor Evans Blue Containing Radiotherapeutics
The invention pertains to a radiotherapeutic against neuroendocrine
tumors that express somatostatin receptor. Radionuclide therapies
directed against tumors that express somatostatin receptors (SSTRs)
have proven effective for the treatment of advanced, low- to
intermediate-grade neuroendocrine tumors. The subject radiotherapeutic
covered by the subject patent estate includes a somatostatin (SST)
peptide derivative like octreotate (TATE), conjugated to an Evans Blue
(EB) analog, and further chelated via DOTA to therapeutic
radionuclide\177\Lu, a beta emitter. The EB analog reversibly binds to
circulating serum albumin and improves the pharmacokinetics of SST
peptide derivatives and reduce peptide-receptor radionuclide therapy
toxicity. EB analog conjugated to octreotate (EB-DOTATATE) has been
shown by the inventors to provide reversible albumin binding in vivo
and extended half-life in circulation. When EB-TATE is slowly released
into the tumor microenvironment, tumor uptake and internalization into
SSTR positive tumors resulted in delivery of radioactive particles and
tumor cell killing. EB-TATE displayed significantly more favorable
pharmacokinetics than TATE alone by achieving higher tumor to non-tumor
penetration as evidenced by positron emission tomography.
Potential Commercial Applications:
Cancer therapeutics
Higher stability/Lower toxicity
Development Stage:
Early stage
Inventors: Xiaoyuan Chen and Orit Jacobson Weiss (both of NIBIB).
Intellectual Property: HHS Reference No. E-150-2016-1;
International Patent Application PCT/US2017/031696.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
[email protected].
Dated: July 20, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-16839 Filed 8-6-18; 8:45 am]
BILLING CODE 4140-01-P
